Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherMINIREVIEWS

Targeting Protein Serine/Threonine Phosphatases for Drug Development

Jamie L. McConnell and Brian E. Wadzinski
Molecular Pharmacology June 2009, 75 (6) 1249-1261; DOI: https://doi.org/10.1124/mol.108.053140
Jamie L. McConnell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian E. Wadzinski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity.

Footnotes

  • This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK070787]; the National Institutes of Health National Institute of General Medicine [Grant GM051366]; the Vanderbilt-Ingram Cancer Center [Grant CA68485]; the Center for Molecular Neuroscience [Grant MH19732]; and the Vanderbilt Diabetes Research and Training Center [Grant DK20593].

  • ABBREVIATIONS: CnA, calcineurin A subunit; CnB, calcineurin B subunit; CsA, cyclosporin A; Cyp, cyclophilin; eIF2α, eukaryotic initiation factor-2α; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; FCP, transcription factor II F-interacting carboxyl terminal domain phosphatase; FK506, tacrolimus; FKBP12, FK506 binding protein of 12 kDa; GADD34, growth arrest and DNA damage gene 34; HDAC, histone deacetylase; HSV, herpes simplex virus; IκB, inhibitor of κB; IKK, IκB kinase; INCA, inhibitors of NFAT-calcineurin association; MAP, mitogen-activated protein; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; NF-κB, nuclear factor-κB; NFAT, nuclear factor of activated T cells; Plk1, polo-like kinase 1; PP1, protein serine/threonine phosphatase 1; PP1c, catalytic subunit of PP1; PP2, protein serine/threonine phosphatase 2; PPM, magnesium/manganese-dependent protein phosphatase; PPP, phosphoprotein phosphatase; PSTP, protein serine/threonine phosphatase; PTP, protein tyrosine phosphatase; sal, salubrinal; SAR, structure-activity relationship; SV40, simian virus 40; TNF, tumor necrosis factor-α; TSA, trichostatin A.

    • Received October 28, 2008.
    • Accepted March 19, 2009.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 75 (6)
Molecular Pharmacology
Vol. 75, Issue 6
1 Jun 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting Protein Serine/Threonine Phosphatases for Drug Development
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherMINIREVIEWS

Targeting Protein Serine/Threonine Phosphatases for Drug Development

Jamie L. McConnell and Brian E. Wadzinski
Molecular Pharmacology June 1, 2009, 75 (6) 1249-1261; DOI: https://doi.org/10.1124/mol.108.053140

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherMINIREVIEWS

Targeting Protein Serine/Threonine Phosphatases for Drug Development

Jamie L. McConnell and Brian E. Wadzinski
Molecular Pharmacology June 1, 2009, 75 (6) 1249-1261; DOI: https://doi.org/10.1124/mol.108.053140
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Overview of Protein Serine/Threonine Phosphatases
    • Targeting Serine/Threonine Phosphatase Catalytic Subunits for Drug Development
    • Targeting Serine/Threonine Phosphatase Complexes for Drug Development
    • Summary
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanotransduction in Cancer
  • Intracellular mGlu5
  • NADPH Oxidases and Influenza Virus Infections
Show more Minireviews

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics